CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
China
Regenerative Medicine Center and Red Blood Cell Disorders Center, Tianjin, Tianjin Municipality Age range
18 Years and older
Last updated December 2024